Search Within

Department of Medicine

Formats
  1. Journal Article (19590)
  2. Meeting Abstract (16038)
  3. Review (1150)
  4. Book Section (934)
  5. Editorial (608)
  6. Research Letter (314)
  7. Conference Paper (301)
  8. Guidelines (295)
  9. Correspondence (236)
  10. Miscellaneous (90)
  11. Book Whole (61)
Groups
  1. Solid Tumor Oncology Division (22319)
  2. Hematologic Malignancies, Division of (13276)
  3. Center for Hematologic Malignancies (11060)
  4. GSK Faculty (10645)
  5. Survivorship Research (9329)
  6. Division of Subspecialty Medicine (7534)

More Groups

People
  1. Robert Motzer (1248)
  2. Howard Scher (1132)
  3. Sergio Giralt (1069)
  4. Miguel-Angel Perales (943)
  5. Clifford Hudis (905)
  6. Jedd Wolchok (905)

More People

Years
  1. 2025 (1066)
  2. 2024 (2291)
  3. 2023 (2452)
  4. 2022 (2621)
  5. 2021 (2534)
  6. 2020 (2563)

More Years

Publications
  1. Journal of Clinical Oncology (6125)
  2. Blood (3722)
  3. Annals of Oncology (1398)
  4. Cancer Research (1238)
  5. Clinical Cancer Research (902)
  6. Biology of Blood and Marrow Transplantation (679)

More Publications

Publishers
  1. American Society of Clinical Oncology (6458)
  2. Elsevier Inc. (4216)
  3. American Society of Hematology (4003)
  4. American Association for Cancer Research (2896)
  5. Oxford University Press (2286)
  6. Nature Publishing Group (2110)

More Publishers

Results (39617)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Efficacy and safety of asciminib in chronic myeloid leukemia in chronic phase (CML-CP): Interim results from the phase 2 ASC2ESCALAT trial in the cohort of patients (pts) after 1 prior tyrosine kinase inhibitor (TKI)
    Meeting Abstract

    Atallah, E. L.; Levy, M. Y.; Koller, P. B.; Sasaki, K.; Tantravahi, S. K.; Andorsky, D.; Bremer, C. T.; Zeidner, J. F.; Luskin, M. R.; Munker, R.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Five-year analysis of the POLARIX study: Prolonged follow-up confirms positive impact of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) on outcomes
    Meeting Abstract

    Salles, G.; Morschhauser, F.; Sehn, L. H.; Herrera, A. F.; Friedberg, J. W.; Trněný, M.; Lenz, G.; Sharman, J. P.; Herbaux, C.; Burke, J. M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Initial results of a phase 1 first-in-human study of cemsidomide (CFT7455), a novel MonoDAC™ degrader, in patients with non-Hodgkin's lymphoma
    Meeting Abstract

    Horwitz, S.; Jain, S.; Soumerai, J. D.; Tees, M. T.; Stuver, R.; Ali, A.; Leahy, L.; Lobbardi, R.; Chu, R.; Hurh, E.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Dual-targeted therapy with ruxolitinib plus duvelisib for T-cell lymphoma
    Meeting Abstract

    Moskowitz, A.; Ganesan, N.; Chang, T.; Davey, T.; Hancock, H.; Smith, M.; Assini, A.; Sarmasti, L.; Miller, T.; Gibaldi, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Development of a novel prognostic score for relapsed/refractory mature T-cell and NK-cell lymphomas (PIRT): Results from a global peripheral T-cell lymphoma (PETAL) Consortium
    Meeting Abstract

    Koh, M. J.; Han, J. X.; Boussi, L.; Sorial, M. N.; McCabe, S. M.; Peng, L.; Singh, S.; Eche-Ugwu, I. J.; Gabler, J.; Fernandez Turizo, M. J. J.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Integrating genomic & transcriptomic features for noninvasive detection, characterization, and monitoring of T-cell lymphomas
    Meeting Abstract

    Sugio, T.; Nesselbush, M.; Shukla, N.; Garofalo, A.; Mutter, J. A.; Esfahani, M. S.; Alig, S. K.; Shi, S.; Noordenbos, T.; Hamilton, M. P.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Updated analysis of brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for nonbulky, early-stage classical Hodgkin lymphoma
    Meeting Abstract

    Abramson, J. S.; Straus, D. J.; Bartlett, N. L.; Burke, J. M.; Lynch, R. C.; Domenech, E. D.; Hess, B.; Schuster, S.; Linhares, Y.; Ramchandren, R.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Outpatient vs inpatient HiDA consolidation for AML: The MSKCC experience
    Meeting Abstract

    Boussi, L.; Burton, H.; Derkach, A.; Nemirovsky, D.; Ciervo, J.; Tallman, M. S.; Stein, E. M.; Cai, S.
    Blood (2024)

    Fulltext@MSK | Save
  • Development of CAR T cells targeting U5 snRNP200 for the treatment of acute myeloid and B-lymphoid leukemias
    Meeting Abstract

    Fujino, T.; Lewis, J.; Chen, B. Y.; Sievers, Q.; Cai, W.; Yoo, S.; Mathew, S.; Souness, S.; Burns, E. R.; Um, J. S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Mis-splicing derived neoantigens and cognate T cell receptors in splicing factor mutant myeloid neoplasms
    Meeting Abstract

    Kim, W. J.; Crosse, E. I.; De Neef, E.; Etxeberria, I.; Sabio, E.; Wang, E.; Bewersdorf, J. P.; Lu, S. X.; Belleville, A.; Fox, N.; more...
    Blood (2024)

    Fulltext@MSK | Save